As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Drugs like Ozempic and Wegovy have the power to block the forces driving obesity, but the knock-on societal effects may not necessarily be so positive ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

Drugs like Ozempic, Wegovy, and Saxenda have become hugely popular. But could they cause psychological side effects in their ...

Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration to look into foreign-made active pharmaceutical ingredients he ...

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list.

Is the era of sourcing cheaper weight loss drugs from the internet over? High demand for GLP-1 agonists — prescription drugs ...